Le Lézard1h
Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus
Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024Iqirvo approved for use in the U.S. in June 2024, in the E.U. in September ...
Ipsen Pharma: Iqirvo (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus
Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024Iqirvo approved for use in the U.S. in June 2024, in the E.U. in September 202 ...
CNET6d
Best Alkaline Batteries for 2024
Alkaline batteries can be used in a wide range of toys and tech items, and they're more affordable than lithium batteries. Check out CNET's picks of the best alkaline batteries before you stock up ...
Medscape6d
Pharmacology of Silymarin
It has been shown that silymarin is as active as quercetin and dihydroquercetin, and more active than quercitrin, in terms of antiperoxidant activity, independent of the experimental model used to ...
Medscape4d
Mortality Associated with Hormone Replacement Therapy in Younger and Older Women
In the younger group, with mean age 54 years at baseline, HRT was associated with a reduction in total mortality of 39%. In the older group, with mean age 66 years, HRT was not associated with a ...
Le Lézard2d
Daiichi Sankyo to Showcase TURALIO® Research in Patients with Tenosynovial Giant Cell Tumor at CTOS
Daiichi Sankyo (TSE: 4568) will highlight new clinical research and real-world data from seven abstracts for TURALIO® (pexidartinib) at the Connective Tissue Oncology Society (#CTOS2024) 2024 Annual ...